NASDAQ
Progyny (PGNY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term....
Edgestream Partners L.P. increased its holdings in shares of Progyny, Inc. (NASDAQ: PGNY) by 99.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange C...
CEO Anevski now owns $17 million worth of Progyny. Progyny's stock popped roughly 8% the day of the announcement....
Progyny (PGNY) possesses solid growth attributes, which could help it handily outperform the market....
NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in family building solutions, today announced new men's health research exploring experiences and views on fer...
Progyny (PGNY) surges after strong Q3 earnings, robust client growth, and a $200M share buyback, signaling renewed momentum and market confidence. PGNY overcame Amazon's departure by adding new client...
Progyny is a leader in fertility benefits, offering employers comprehensive, outcomes-based solutions that improve treatment success and manage costs. Its focused model has driven strong demand and se...
Progyny (PGNY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues....
Investors interested in stocks from the Medical Services sector have probably already heard of Progyny (PGNY) and HealthEquity (HQY). But which of these two stocks is more attractive to value investor...
Aviva PLC trimmed its holdings in shares of Progyny, Inc. (NASDAQ: PGNY) by 23.7% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC...
No price data available for this timeframe.